Amazon.com Inc (AMZN) has stood preliminary talks with generic pharmaceutical makers about potentially presenting the drug purchasing market, people familiar with the matter communicated CNBC.
Sources said the Seattle, Washington-based company discussed its plots with generic drug giants, including Mylan N.V. (MYL) and Novartis AG (NVS)-owned Sandoz. The gossips were described as high-level and vague, although one source claimed that they revolved about Amazon’s ambition to start purchasing and supplying drugs.
Generic industrialists are believed to be open to the idea of striking up a relationship with Amazon. Shares in Mylan were 2 percent expensive in pre-market trading, indicating that investors, too, are encouraged by this conceivability.
Speculation about Amazon’s next move was further corroborated by Leerink. In note allotted to investors on Thursday, the health care investment bank confirmed that Sandoz’s president and wildly of North America operations Peter Goldschmidt “met and discussed with Amazon its scripts for getting into the U.S. healthcare market” at a recent biopharma event. The note didn’t brilliance whether the company intends to become a drug wholesaler or sell generic medications as a retailer, but added that Sandoz doesn’t await Amazon’s plans to have a “major impact” on its business.
If rumors that Amazon is set to order drugs are true, its biggest competitors will be McKesson Corp. (MCK), Primary Health Inc. (CAH) and AmerisourceBergen Corp. (ABC). All three companies have come covered by pressure in recent months from talk that Amazon, a famous disruptor of various industries, is keen to steal business away from them.
In November, Amazon told regulators that the druggists licenses it recently obtained from Tennessee and Indiana will be second-hand to sell medical devices and supplies, rather than prescription analgesics. In response to that report, provided by Jefferies, Adam Fein, president of Pembroke Consulting and a upper supply chain expert, said he doesn’t think Amazon set ups a significant threat to other distributors. (See also: Amazon Will Not Stockpile or Ship Drugs: Report.)
“There has been a massive overreaction to the Amazon presage,” Fein said. “I would never underestimate Amazon. But I remain a little skeptical of Amazon’s ability and desire to fundamentally alter the drug direct [as] the incumbents will have many opportunities to defend their predication, capture value from internet technologies, and streamline distribution.”
Interim, Walgreens Boots Alliance Inc.’s (WBA) CEO Stefano Pessina said at the Forbes Healthcare Crown on Wednesday that Amazon might be put off by regulatory hurdles. “I believe that they compel not come in an industry so complicated as our industry,” Pessina said, according to CNBC. “I in in the end they will use their technology in a different way.”
CNBC added that bosses of unsurpassed drug manufacturers have been questioned about the prospect of disposing with Amazon on recent quarterly earnings conference calls. The rejoinders are said to have been enthusiastic, even though formal dialogues are not believed to have yet taken place. (See also: Evaluating Amazon’s Chances in the Pharma Persistence.)